298 related articles for article (PubMed ID: 31150808)
1. Danazol oral absorption modelling in the fasted dog: An example of mechanistic understanding of formulation effects on drug pharmacokinetics.
Pade D; Jamei M; Turner DB; Mistry B; Martinez MN
Eur J Pharm Biopharm; 2019 Aug; 141():191-209. PubMed ID: 31150808
[TBL] [Abstract][Full Text] [Related]
2. An in vitro digestion test that reflects rat intestinal conditions to probe the importance of formulation digestion vs first pass metabolism in Danazol bioavailability from lipid based formulations.
Anby MU; Nguyen TH; Yeap YY; Feeney OM; Williams HD; Benameur H; Pouton CW; Porter CJ
Mol Pharm; 2014 Nov; 11(11):4069-83. PubMed ID: 25265395
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation.
Porter CJ; Kaukonen AM; Boyd BJ; Edwards GA; Charman WN
Pharm Res; 2004 Aug; 21(8):1405-12. PubMed ID: 15359575
[TBL] [Abstract][Full Text] [Related]
4. Effects of absorption-modifying excipients on jejunal drug absorption in simulated fasted and fed luminal conditions.
Roos C; Dahlgren D; Sjögren E; Sjöblom M; Hedeland M; Lennernäs H
Eur J Pharm Biopharm; 2019 Sep; 142():387-395. PubMed ID: 31306752
[TBL] [Abstract][Full Text] [Related]
5. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
[TBL] [Abstract][Full Text] [Related]
6. Methacrylate-Copolymer Eudragit EPO as a Solubility-Enabling Excipient for Anionic Drugs: Investigation of Drug Solubility, Intestinal Permeability, and Their Interplay.
Fine-Shamir N; Dahan A
Mol Pharm; 2019 Jul; 16(7):2884-2891. PubMed ID: 31120762
[TBL] [Abstract][Full Text] [Related]
7. Effect of cyclodextrin concentration on the oral bioavailability of danazol and cinnarizine in rats.
Holm R; Olesen NE; Hartvig RA; Jørgensen EB; Larsen DB; Westh P
Eur J Pharm Biopharm; 2016 Apr; 101():9-14. PubMed ID: 26776271
[TBL] [Abstract][Full Text] [Related]
8. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.
Darwich AS; Neuhoff S; Jamei M; Rostami-Hodjegan A
Curr Drug Metab; 2010 Nov; 11(9):716-29. PubMed ID: 21189140
[TBL] [Abstract][Full Text] [Related]
9. Soluplus® as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo.
Linn M; Collnot EM; Djuric D; Hempel K; Fabian E; Kolter K; Lehr CM
Eur J Pharm Sci; 2012 Feb; 45(3):336-43. PubMed ID: 22172603
[TBL] [Abstract][Full Text] [Related]
10. Toward Successful Cyclodextrin Based Solubility-Enabling Formulations for Oral Delivery of Lipophilic Drugs: Solubility-Permeability Trade-Off, Biorelevant Dissolution, and the Unstirred Water Layer.
Fine-Shamir N; Beig A; Zur M; Lindley D; Miller JM; Dahan A
Mol Pharm; 2017 Jun; 14(6):2138-2146. PubMed ID: 28505451
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
Fei Y; Kostewicz ES; Sheu MT; Dressman JB
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
[TBL] [Abstract][Full Text] [Related]
12. Active intestinal drug absorption and the solubility-permeability interplay.
Porat D; Dahan A
Int J Pharm; 2018 Feb; 537(1-2):84-93. PubMed ID: 29102702
[TBL] [Abstract][Full Text] [Related]
13. Non-linear increases in danazol exposure with dose in older vs. younger beagle dogs: the potential role of differences in bile salt concentration, thermodynamic activity, and formulation digestion.
Anby MU; Williams HD; Feeney O; Edwards GA; Benameur H; Pouton CW; Porter CJ
Pharm Res; 2014 Jun; 31(6):1536-52. PubMed ID: 24477676
[TBL] [Abstract][Full Text] [Related]
14. Effect of lipids on absorption of carvedilol in dogs: Is coadministration of lipids as efficient as a lipid-based formulation?
Alskär LC; Parrow A; Keemink J; Johansson P; Abrahamsson B; Bergström CAS
J Control Release; 2019 Jun; 304():90-100. PubMed ID: 31047962
[TBL] [Abstract][Full Text] [Related]
15. Application of dissolution/permeation system for evaluation of formulation effect on oral absorption of poorly water-soluble drugs in drug development.
Kataoka M; Sugano K; da Costa Mathews C; Wong JW; Jones KL; Masaoka Y; Sakuma S; Yamashita S
Pharm Res; 2012 Jun; 29(6):1485-94. PubMed ID: 22134778
[TBL] [Abstract][Full Text] [Related]
16. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study.
Kuentz M; Nick S; Parrott N; Röthlisberger D
Eur J Pharm Sci; 2006 Jan; 27(1):91-9. PubMed ID: 16219449
[TBL] [Abstract][Full Text] [Related]
17. Quantitative prediction of formulation-specific food effects and their population variability from in vitro data with the physiologically-based ADAM model: a case study using the BCS/BDDCS Class II drug nifedipine.
Patel N; Polak S; Jamei M; Rostami-Hodjegan A; Turner DB
Eur J Pharm Sci; 2014 Jun; 57():240-9. PubMed ID: 24060671
[TBL] [Abstract][Full Text] [Related]
18. Effect of Surfactant-Bile Interactions on the Solubility of Hydrophobic Drugs in Biorelevant Dissolution Media.
Vinarov Z; Katev V; Burdzhiev N; Tcholakova S; Denkov N
Mol Pharm; 2018 Dec; 15(12):5741-5753. PubMed ID: 30351956
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Bioavailability Strategy for Decisions on Clinical Drug Formulation Development: An In Depth Analysis.
Van den Bergh A; Van Hemelryck S; Bevernage J; Van Peer A; Brewster M; Mackie C; Mannaert E
Mol Pharm; 2018 Jul; 15(7):2633-2645. PubMed ID: 29799758
[TBL] [Abstract][Full Text] [Related]
20. Increasing the proportional content of surfactant (Cremophor EL) relative to lipid in self-emulsifying lipid-based formulations of danazol reduces oral bioavailability in beagle dogs.
Cuiné JF; Charman WN; Pouton CW; Edwards GA; Porter CJ
Pharm Res; 2007 Apr; 24(4):748-57. PubMed ID: 17372700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
